Stryker's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Stryker (SYK)

Q1 2012 Earnings Call

April 17, 2012 4:30 pm ET


Curt R. Hartman - Interim Chief Executive Officer, Chief Financial Officer and Vice President

Katherine A. Owen - Vice President of Strategy & Investor Relations


Robert A. Hopkins - BofA Merrill Lynch, Research Division

Kristen M. Stewart - Deutsche Bank AG, Research Division

Michael Matson - Mizuho Securities USA Inc., Research Division

Derrick Sung - Sanford C. Bernstein & Co., LLC., Research Division

Michael N. Weinstein - JP Morgan Chase & Co, Research Division

Larry Biegelsen - Wells Fargo Securities, LLC, Research Division

Glenn J. Novarro - RBC Capital Markets, LLC, Research Division

Matthew O'Brien - William Blair & Company L.L.C., Research Division

Steve Beuchaw - Morgan Stanley, Research Division

Matthew S. Miksic - Piper Jaffray Companies, Research Division

Bruce M. Nudell - Crédit Suisse AG, Research Division

Richard Newitter - Leerink Swann LLC, Research Division

Rajeev Jashnani - UBS Investment Bank, Research Division

Matthew Taylor - Barclays Capital, Research Division

Joshua T. Jennings - Cowen and Company, LLC, Research Division

Jason Wittes - Caris & Company, Inc., Research Division

Jeffrey D. Johnson - Robert W. Baird & Co. Incorporated, Research Division

William J. Plovanic - Canaccord Genuity, Research Division

David H. Roman - Goldman Sachs Group Inc., Research Division

Joanne K. Wuensch - BMO Capital Markets U.S.



Good day, ladies and gentlemen, and welcome to the First Quarter 2012 Stryker Earnings Conference Call. My name is Derek, and I'll be your operator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. I would now like to take the time and read the Safe Harbor statement.

Certain statements made in this presentation may contain information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause the company's actual results to differ materially from those expressed or implied in such statements.

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal